NPCE
Earnings, but make it a growth checkup
NeuroPace opened Q1 2026 with a decent little flex: revenue hit $22.1 million, up 8% year over year, as the RNS system kept doing the heavy lifting. Ex-Dixie Medical, revenue was basically the same story at $22 million, which tells you the core business is still carrying the weight.
The part investors actually care about
The bigger headline might be the guide-up. Management raised full-year 2026 revenue expectations to $99 million-$101 million from $98 million-$100 million. That’s not a moonshot, but it does signal confidence that the patient funnel, service revenue visibility, and commercial push are all moving in the right direction.
A few things stood out from the call:
- Active prescriber accounts and patient pipeline hit new highs
- Non-GAAP gross margin came in at 82.5%, which is the kind of number that makes finance people smile
- Non-GAAP operating expenses rose 10%, showing the company is spending to grow, but not recklessly
FDA in the mix, because biotech can’t just chill
NeuroPace also said the FDA mid-cycle review for the Nautilus PMA supplement was productive, and it expects a mid-year decision on the IGE indication expansion. On top of that, the company is still pushing its AI tools, including ECOCHG Assistant, which it expects to get approved in Q2 2026.
That matters because NeuroPace isn’t just selling a device here — it’s trying to widen the moat around a therapy platform. If the FDA keeps saying yes, the addressable market gets bigger, and the revenue story gets a lot more interesting.
Big picture: this wasn’t a fireworks quarter, but it was the kind investors like — steady growth, better guidance, and a pipeline that looks more like a business than a science project.